| Identification | More | [Name]
Cinepazide maleate | [CAS]
26328-04-1 | [Synonyms]
CINEPAZIDE MALEATE
1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazinem
1-(4-((3’,4’,5’-trimethoxycinnamoyl)-1-piperazinyl)acetyl)pyrrolidinemaleate
4-(3,4,5-trimethoxycinnamoyl)-1-(1-pyrrolidinyl)carbonylmethylpiperazinemale
brendil
maleatedecinepazide
md67350
piperazine,1-((1-pyrrolidinylcarbonyl)methyl)-4-(3’,4’,5’-trimethoxycinnamoyl)
vasodistal
1-(2-oxo-2-pyrrolidin-1-ylethyl)-4-[3-(3,4,5-trimethoxyphenyl)acryloyl]piperazine monomaleate
piperazine, 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3',4',5'-trimethoxycinnamoyl) 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazi ne m 1-(4-((3',4',5'-trimethoxycinnamoyl)-1-piperazinyl)acetyl)pyrrolidine maleate 4-(3,4,5-trimethoxycinnamoyl)-1-(1-pyrrolidinyl)carbonylmethylpiperazine male brendil
1-[(1-Pyrrolidinylcarbonyl)methyl]-4-(3,4,5-trimethoxycinnamoyl)piperazine maleate
DD-3357 | [EINECS(EC#)]
247-613-1 | [Molecular Formula]
C26H35N3O9 | [MDL Number]
MFCD01320526 | [Molecular Weight]
533.57 | [MOL File]
26328-04-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
135° | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
Off-White | [Water Solubility ]
H2O: 20mg/mL, clear | [Merck ]
14,2291 | [InChIKey]
XSTJTOKYCAJVMJ-GVTSEVKNSA-N | [SMILES]
C1(OC)C=C(C=C(OC)C=1OC)/C=C/C(=O)N1CCN(CC(=O)N2CCCC2)CC1.C(/C(=O)O)=C/C(=O)O | [CAS DataBase Reference]
26328-04-1(CAS DataBase Reference) |
| Safety Data | Back Directory | [WGK Germany ]
WGK 3 | [HS Code ]
2933.59.5300 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral | [Toxicity]
LD50 in mice, rats (mg/kg): 1000, 1310 orally; 617, 414 i.v. (Pourrias) |
| Hazard Information | Back Directory | [Uses]
Cinepazide maleate is a maleate salt form of cinepazide which is a vasodilator. | [Biological Activity]
Cinepazide maleate is a vasodilator used clinically in China used in China for the treatment of cardiovascular and cerebrovascular diseasesand peripheral vascular diseases. Cinepazide maleate is thought to act as a potentiator of adenosine A2 receptors and has also been characterized as a calcium channel blocker. It was withdrawn for agranulocytosis in several countries. | [in vivo]
Cinepazide Maleate (intravenous?injection; 30 mg/kg) potentiates the vertebral vasodilator response of dogs to intravertebral adenosine and cyclic AMP, while cinnarizine reduces their vasodilator effects[1].Cinepazide Maleate (intravertebral injection; 1-10 mg/kg) increases vertebral blood flow in a dose-related manner?in dogs[1]. |
|
|